Patents by Inventor Patrick Corsino

Patrick Corsino has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
    Patent number: 11224657
    Abstract: A composition includes a pharmaceutical tablet dosage form configured to disintegrate in oral saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein, the dosage form including a therapeutically effective amount of melatonin in a carrier matrix, a disintegrant, and a sufficient amount of acid to impart the pH to the saliva, the amount of disintegrant being sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: January 18, 2022
    Assignee: Société des Produits Nestlé S. A.
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
    Patent number: 11224658
    Abstract: A composition includes a pharmaceutical dosage form configured to disintegrate in oral saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein, the dosage form including a therapeutically effective amount of melatonin in a polymer carrier matrix and a sufficient amount of acid to impart the pH to the saliva, the amount of disintegrant being sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Grant
    Filed: May 13, 2020
    Date of Patent: January 18, 2022
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
    Patent number: 10960075
    Abstract: A composition includes an oral thin film pharmaceutical dosage form configured to disintegrate in saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein. The dosage form includes a therapeutically effective amount of melatonin in a polymer carrier matrix and a sufficient amount of acid to impart the pH to the saliva. The dosage can completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: March 30, 2021
    Assignee: Société des Produits Nestlé S.A.
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Orally Dissolving Melatonin Formulation With Acidifying Agent That Renders Melatonin Soluble In Saliva
    Publication number: 20200268886
    Abstract: A composition includes a pharmaceutical tablet dosage form configured to disintegrate in oral saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein, the dosage form including a therapeutically effective amount of melatonin in a carrier matrix, a disintegrant, and a sufficient amount of acid to impart the pH to the saliva, the amount of disintegrant being sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Application
    Filed: May 13, 2020
    Publication date: August 27, 2020
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Orally Dissolving Melatonin Formulation With Acidifying Agent That Renders Melatonin Soluble In Saliva
    Publication number: 20200268887
    Abstract: A composition includes a pharmaceutical dosage form configured to disintegrate in oral saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein, the dosage form including a therapeutically effective amount of melatonin in a polymer carrier matrix and a sufficient amount of acid to impart the pH to the saliva, the amount of disintegrant being sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Application
    Filed: May 13, 2020
    Publication date: August 27, 2020
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Orally Dissolving Melatonin Formulation With Acidifying Agent That Renders Melatonin Soluble In Saliva
    Publication number: 20200069803
    Abstract: A composition includes an oral thin film pharmaceutical dosage form configured to disintegrate in saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein. The dosage form includes a therapeutically effective amount of melatonin in a polymer carrier matrix and a sufficient amount of acid to impart the pH to the saliva. The dosage can completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Application
    Filed: November 6, 2019
    Publication date: March 5, 2020
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
    Patent number: 10500280
    Abstract: A composition includes a pharmaceutical dosage form configured to dinsintegrate in saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein. The dosage form includes a therapeutically effective amount of melatonin in a carrier matrix, a disintegrant, and a sufficient amount of acid to impart the pH to the saliva. The amount of disintegrant is sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Grant
    Filed: June 15, 2018
    Date of Patent: December 10, 2019
    Assignee: Physician's Seal, LLC
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Orally Dissolving Melatonin Formulation With Acidifying Agent That Renders Melatonin Soluble In Saliva
    Publication number: 20180360967
    Abstract: A composition includes a pharmaceutical dosage form configured to dinsintegrate in saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein. The dosage form includes a therapeutically effective amount of melatonin in a carrier matrix, a disintegrant, and a sufficient amount of acid to impart the pH to the saliva. The amount of disintegrant is sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
    Type: Application
    Filed: June 15, 2018
    Publication date: December 20, 2018
    Inventors: Syed M. Shah, Daniel Hassan, Fred Hassan, Patrick Corsino
  • Cyclin dependent kinase inhibitors
    Patent number: 8569356
    Abstract: The invention relates to cyclin dependent kinase inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions for treating cell proliferative disorders, especially cancer.
    Type: Grant
    Filed: October 25, 2006
    Date of Patent: October 29, 2013
    Assignee: University of Florida Research Foundation, Inc.
    Inventors: David A. Ostrov, Brian K. Law, Patrick Corsino
  • Cyclin Dependent Kinase Inhibitors
    Publication number: 20100035940
    Abstract: The invention relates to cyclin dependent kinase inhibitor compounds and methods of identifying and using them. The invention further relates to pharmaceutical compositions for treating cell proliferative disorders, especially cancer.
    Type: Application
    Filed: October 25, 2006
    Publication date: February 11, 2010
    Applicant: University of Flordia Research Foundation
    Inventors: David A. Ostrov, Brian Keith Law, Patrick Corsino